With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.
Site Search
The Cystic Fibrosis Foundation organized a multidisciplinary committee to develop a nutrition position paper to provide interim advice and considerations to the CF community around CF nutrition based on the rapidly changing nutrition landscape in CF.
Our understanding and treatment of cystic fibrosis has evolved significantly since Dr. Dorothy Andersen first discovered the disease in 1938, but harmful misconceptions around contagion, prevalence, and symptoms pervade. Here are key facts to know about this rare, genetic condition.
When you have cystic fibrosis, there are potential complications related to pregnancy. But as part of the planning process, you can learn more about these complications and how to partner with your CF care team to evaluate these risks based on your personal situation.
These evidence-based guidelines were created by a multidisciplinary committee to help cystic fibrosis specialists and primary care providers who care for people with CFTR-related metabolic disorder and their families. It should supplement the standard care provided in primary care.